Anebulo Pharmaceuticals Inc

NASDAQ:ANEB  
6.60
-0.40 (-5.71%)
Products, Regulatory

Anebulo Pharmaceuticals Announces Initiation Of Phase 2 Clinical Study Evaluating ANEB-001 For The Treatment Of Acute Cannabinoid Intoxication

Published: 01/03/2022 12:31 GMT
Anebulo Pharmaceuticals Inc (ANEB) - Anebulo Pharmaceuticals Announces Initiation of Phase 2 Clinical Study Evaluating Aneb-001 for the Treatment of Acute Cannabinoid Intoxication.
Anebulo Pharmaceuticals Inc - Affirms Expectations for Initial Topline Results in 1h 2022.
Anebulo Pharmaceuticals Inc - Company Expects to Submit Ind in 1q 2022 for Aneb-001.